ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
6,021.63
0.57%
US Tech 100
20,298.40
-0.36%
Dow Jones
44,860.31
0.28%
Brent Oil
72.635
0.26%
Bitcoin
93,435.65
1.59%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Carisma Therapeutics Inc (CARM)

  7. Carisma Therapeutics Inc (CARM) News

CARM

Carisma Therapeutics (CARM)

Carisma Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CARM
DateTimeSourceHeadlineSymbolCompany
11/17/20247:30AMPR Newswire (US)Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024NASDAQ:CARMCarisma Therapeutics Inc
11/08/20247:30AMPR Newswire (US)Carisma Unveils Promising Pre-Clinical Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular CarcinomaNASDAQ:CARMCarisma Therapeutics Inc
11/07/20247:39AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CARMCarisma Therapeutics Inc
11/07/20247:35AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CARMCarisma Therapeutics Inc
11/07/20247:30AMPR Newswire (US)Carisma Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business HighlightsNASDAQ:CARMCarisma Therapeutics Inc
11/06/202411:45AMBusiness WireCARMILA: Information Concerning the Total Number of Voting Rights and ShareNASDAQ:CARMCarisma Therapeutics Inc
11/06/202411:45AMBusiness WireCARMILA : Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L.233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des marchés financiersNASDAQ:CARMCarisma Therapeutics Inc
11/05/20249:05AMPR Newswire (US)Carisma Therapeutics to Present New Data on Anti-GPC3 In Vivo CAR-M Therapy for Hepatocellular Carcinoma at SITC 2024NASDAQ:CARMCarisma Therapeutics Inc
11/01/20244:31PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CARMCarisma Therapeutics Inc
11/01/20244:30PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CARMCarisma Therapeutics Inc
10/30/20244:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CARMCarisma Therapeutics Inc
10/30/20244:30PMPR Newswire (US)Carisma Therapeutics Announces Changes to its Board of DirectorsNASDAQ:CARMCarisma Therapeutics Inc
10/17/202411:45AMBusiness WireCarmila: Third-quarter 2024 Financial InformationNASDAQ:CARMCarisma Therapeutics Inc
10/17/202411:45AMBusiness WireCarmila : Information financière au 30 septembre 2024NASDAQ:CARMCarisma Therapeutics Inc
10/16/20249:54AMBusiness WireCARMILA : COMMUNIQUÉ DE PRESSE EN DATE DU 16 OCTOBRE 2024NASDAQ:CARMCarisma Therapeutics Inc
10/11/20244:49PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CARMCarisma Therapeutics Inc
10/04/20249:05AMPR Newswire (US)Carisma Therapeutics Announces Upcoming Presentations at SITC 2024NASDAQ:CARMCarisma Therapeutics Inc
10/02/202411:45AMBusiness WireCarmila : Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L.233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des marchés financiersNASDAQ:CARMCarisma Therapeutics Inc
10/02/202411:45AMBusiness WireCarmila: Information Concerning the Total Number of Voting Rights and ShareNASDAQ:CARMCarisma Therapeutics Inc
09/25/20246:25AMBusiness WireCARMILA : COMMUNIQUÉ DE PRESSE EN DATE DU 25 SEPTEMBRE 2024NASDAQ:CARMCarisma Therapeutics Inc
09/24/202412:26PMBusiness WireCARMILA : COMMUNIQUÉ DE PRESSE EN DATE DU 24 SEPTEMBRE 2024NASDAQ:CARMCarisma Therapeutics Inc
09/24/202412:10PMBusiness WireSUCCES DE L'OFFRE DE RACHAT SUR LES OBLIGATIONS CARMILA AVEC UN MONTANT TOTAL RACHETE DE 200.100.000 D'EUROS D'OBLIGATIONSNASDAQ:CARMCarisma Therapeutics Inc
09/24/202412:10PMBusiness WireSuccessful Completion of Tender Offer on Carmila’s Bonds With €200,100,000 of Bonds TenderedNASDAQ:CARMCarisma Therapeutics Inc
09/17/202412:30PMBusiness WireCarmila Successfully Issues Inaugural €300M 7-Year Green Bond, Paying a Fixed Annual Coupon of 3.875%NASDAQ:CARMCarisma Therapeutics Inc
09/17/202412:30PMBusiness WireSUCCES DE L’EMISSION INAUGURALE D’UN « GREEN BOND » DE 300 M€ ET DE MATURITE 7 ANS, AVEC UN COUPON FIXE ANNUEL DE 3,875%NASDAQ:CARMCarisma Therapeutics Inc
09/16/20244:47AMBusiness WireCarmila Announces the Launch of a Tender Offer on Its Existing Notes Maturing in May 2027, March 2028, October 2028 and April 2029, and Announces Its Intention to Issue New NotesNASDAQ:CARMCarisma Therapeutics Inc
09/16/20244:47AMBusiness WireCARMILA ANNONCE LE LANCEMENT D'UNE OFFRE DE RACHAT SUR SES OBLIGATIONS EXISTANTES VENANT À ÉCHÉANCE EN MAI 2027, MARS 2028, OCTOBRE 2028 ET AVRIL 2029, ET ANNONCE SON INTENTION D'ÉMETTRE DE NOUVELLES OBLIGATIONSNASDAQ:CARMCarisma Therapeutics Inc
09/10/20247:30AMPR Newswire (US)Carisma and Moderna Expand Collaboration to Develop Two In Vivo CAR-M Therapies for Autoimmune DiseasesNASDAQ:CARMCarisma Therapeutics Inc
09/09/202411:45AMBusiness WireCarmila : Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L.233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des marchés financiersNASDAQ:CARMCarisma Therapeutics Inc
09/09/202411:45AMBusiness WireCarmila: Information Concerning the Total Number of Voting Rights and Share, Provided Pursuant to Article L.233-8 II of the Code de commerce (French Commercial Code) and Article 223-16 of the Règlement général de l’Autorité des marchés financiersNASDAQ:CARMCarisma Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:CARM

Your Recent History

NASDAQ
SAVA
Cassava Sciences
USOTC
CBDW
1606 (PK)
USOTC
ENZC
Enzolytics (PK)
USOTC
MONI
Moon Equity (PK)
NASDAQ
ENTA
Enanta Pharmaceuticals
NASDAQ
AVXL
Anavex Life Sciences
USOTC
GDVM
Global Developments (PK)
USOTC
DBMM
Digital Brand Media and ... (PK)
USOTC
BMXI
Brookmount Explorations (PK)
NYSE
AMC
AMC Entertainment
USOTC
ERHE
ERHC Energy (CE)
NASDAQ
NB
NioCorp Developments
USOTC
HIRU
Hiru (PK)
USOTC
KBLB
Kraig Biocraft Laborator... (QB)
USOTC
GVSI
Good Vibrations Shoes (PK)
NASDAQ
TSLA
Tesla
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Save up to 60%* for Ultimate Trader

1 year 40%, 2 years 50% and *3 years 60%

*Across 3 years $3395.52 only $1358.21